*Biotechnological production of antigens of Borrelia burgdorferi sensu lato for preparation of prototype of vaccine against Lyme borreliosis.
Public support
Provider
Ministry of Industry and Trade
Programme
Project consortia
Call for proposals
Projektová konsorcia 3 (SMPO200300001)
Main participants
Bioveta, a.s.
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
*Biotechnologie výroby antigenů Borrelia burgdorferi sensu lato pro přípravu prototypu vakcíny proti Lymeské borelióze.
Annotation in Czech
*Výzkum a vývoj biotechnologixckých postupů na úrovni genového inženýrství vedoucí k přípravě proteinových jednotek vhodných pro základní prototypovou formuli subjednotkové vakcíny proti Lymeské borelióze.
Scientific branches
R&D category
PV - Industrial research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
FN - Epidemiology, infection diseases and clinical immunology
CEP - another secondary branch
—
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30302 - Epidemiology<br>30303 - Infectious Diseases<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Acceptable
Solution timeline
Realization period - beginning
Jan 1, 2003
Realization period - end
Jan 1, 2005
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP06-MPO-FD-U/02:2
Data delivery date
Feb 19, 2007
Finance
Total approved costs
31,871 thou. CZK
Public financial support
11,991 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
19,881 thou. CZK